Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysine-specific demethylase 3A (KDM3A) is an iron- and α-ketoglutarate-dependent histone demethylase enzyme in humans, encoded by the KDM3A gene. It specifically demethylates mono- and dimethyl lysine 9 of histone H3 (H3K9me1/2), a key epigenetic mark linked to gene silencing, thus playing a pivotal role in chromatin regulation and transcriptional activation. KDM3A interacts with hormone nuclear receptors, including the androgen receptor, facilitating hormone-responsive gene transcription, and it is required in spermatogenesis, metabolic gene regulation, and adaptation to cellular stress. KDM3A is also a transcriptional coactivator for the JAK2–STAT3 pathway and is implicated in several diseases (notably cancer, obesity, and male infertility), making it an emerging therapeutic target for epigenetic modulation.
Inhibition of demethylase activity (prevents removal of methyl groups from H3K9, leading to altered gene expression/epigenetic state); Blockade of coactivator/interaction with signaling pathways such as JAK2–STAT3
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysine-specific demethylase 3A (KDM3A).